Nivolumab (Opdivo®) for Melanoma

Assessment Status Assessment Process Complete
Drug Nivolumab
Brand Opdivo®
Indication Is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma. Rapid Review
Assessment Process
Rapid review commissioned 28/05/2015
Rapid review completed 16/07/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 30/10/2015
NCPE assessment completed 18/03/2016
NCPE assessment outcome Reimbursement not recommended at the submitted price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.